Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy

Area of Science:

• Oncology
• Pharmacology
• Immunotherapy

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in personalized cancer therapy.
• ADCs combine tumor-specific monoclonal antibodies with potent cytotoxic agents (payloads) for targeted cancer cell delivery.
• Despite targeted delivery, adverse events can occur due to payload release or antigen cross-expression.

Approach:

• This review synthesizes information on adverse events associated with US Food and Drug Administration-approved ADCs used in solid tumors.
• It elaborates on common and serious adverse events encountered with these targeted therapies.
• The review also discusses practical strategies for mitigating toxicity and optimizing therapeutic efficacy.

Key Points:

• ADCs selectively deliver cytotoxic payloads to cancer cells, minimizing damage to healthy tissues.
• Potential adverse events include off-target toxicity from payload release or shared antigen expression.
• Management strategies and dose modifications are crucial for balancing ADC efficacy and patient safety.

Conclusions:

• Understanding and managing adverse events is critical for the successful clinical application of antibody-drug conjugates.
• This review provides guidance for healthcare professionals on optimizing ADC therapy in solid tumors.
• Effective management strategies can enhance patient outcomes and broaden the use of ADCs in cancer treatment.